Wanbury Limited — PPTs, 24-11-2025: Investor Presentation

Wanbury delivered a robust H1 FY26 with revenue up 10.6% YoY to ₹323.2 Cr and PAT soaring 216.5% YoY to ₹28.67 Cr. Q2 FY26 also saw impressive PAT growth of 89% YoY to ₹15.18 Cr, with basic EPS rising 88% YoY to ₹4.58, alongside a slight revenue dip to ₹160.06 Cr (-0.7% YoY). The API segment continues to drive performance, while the Formulations business notably turned EBITDA positive. Strategic expansion in regulated API markets with 4 new molecule launches annually from FY27, along with cost-optimizing backward integration, are key growth drivers. Recent highlights include zero 483 observations in the 6th USFDA inspection for its Patalganga plant and the successful launch of 'C-red' in formulations. Management emphasized strong Q2 EBITDA and PAT growth, crediting cost efficiencies, improved yields, and reduced finance costs, alongside digital transformation efforts. The outlook is focused on sustainable growth, capacity expansion, and operational excellence.